1. No category

Global Major
Depressive Disorder
(MDD) Treatment
Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Major Depressive Disorder (MDD) is one of the most common mental disorder characterized by
persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep
and normal activities. MDD is also referred as clinical depression, major depression, and
unipolar depression or as recurrent depression. The common symptoms associated with this
disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of
worthlessness and reduced ability to think. Increasing number of patients suffering from MDD
has grabbed the attention of MDD drugs manufacturer to invest into MDD treatment market.
Major Depressive Disorder (MDD) Treatment Market: Drivers and Restraints
Work life imbalances due to change in life style, and increase in MDD patient pool are the key
drivers expected to drive the MDD treatment market over the forecasted period. Partnerships
for co-development and co-marketing of MDD drugs among the drug manufactures across the
globe, development of new drugs, and adequate government reimbursement policies have also
fueled the growth of MDD treatment market. However, stringent regulations imposed by various
governments for new drug approval, patent expiries of some blockbuster drugs, risk of
complications with other medications, and related side effects of MDD drugs may hinder the
growth of MDD treatment market over the forecasted period.
Request for sample report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1314
Report
Description
Report Description
•Major Depressive Disorder (MDD) Treatment Market: Segmentation
•The global MDD treatment market is segmented based on drug type used for the
treatment of MDD.
•Antidepressants
• Selective Serotonin Reuptake Inhibitors (Ssris)
• Dopamine Norepinephrine Reuptake Inhibitor
• Serotonin Norepinephrine Reuptake Inhibitor
• Serotonin Modulators
• Norepinephrine-Serotonin Modulator
• Tricyclics and Tetracyclics
• Monoamine Oxidase Inhibitors (MAOIs)
• Irreversible, non-selective inhibitors
• Phenelzine
• Tranylcypromine
• Isocarboxazid
• Irreversible, MAO B selective inhibitor
• Selegiline transdermal
• Reversible, MAO A selective inhibitor
• Moclobemide
Report
Description
Report Description
Atypical antidepressants
Antipsychotics
Major Depressive Disorder (MDD) Treatment Market: Overview
At present, antidepressants are most commonly used drugs for the treatment of MDD,
and has the largest market segment. Major brands of SSRI’s include Citalopram,
Escitalopram, Fluoxetine, Paroxetine, and Sertraline. Bupropion, Mirtazapine, and
Razodone, are atypical antidepressants frequently used for the treatment of MDD. Major
brands of antipsychotics includes Resperidone, Olanzapine, Quetiapine, Ziprasidone, and
Aripiprazole. Global MDD treatment market is expected to grow with a healthy CAGR
owing to increase in MDD patient pool over the forecast period.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1314
Major Depressive Disorder (MDD) Treatment Market: Region-wise Outlook
Geographically, North America market is estimated to hold maximum market revenue
share in global MDD treatment market owing to increase in number of patients suffering
from MDD, and advancement in technology to develop new therapeutic drugs and
followed by Europe and Asia-Pacific respectivily. The market in Asia-Pacific is expected to
expand at a significant CAGR over the forecasted period due to increasing awareness for
depression conditions and complications associated with it. MDD treatment market is
expected to register healthier CAGR in emerging markets such as India, China, and Brazil
compared to other developed regions in the world.
Report
Description
Report Description
Major Depressive Disorder (MDD) Treatment Market: Key Players
Key companies operational in MDD treatment market are Eli Lilly and Company,
Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc,
Sanofi S.A., Shire plc, Novartis AG, Janssen Pharmaceutical, Inc., and others.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705